Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Part of paid clinical trials in Newport Beach, California.

Sponsor
Hoag Memorial Hospital Presbyterian
Study ID
NCT00004039
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • recombinant interferon alfa — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • cyclophosphamide — DRUG
  • doxorubicin hydrochloride — DRUG
  • prednisone — DRUG
  • vincristine sulfate — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa or the monoclonal antibody rituximab with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy plus interferon alfa or rituximab in treating patients who have high risk stage III or stage IV lymphoma.

Key Dates

Start date
Jun 30, 1998
Status verified
Aug 2015
Primary completion
Jan 31, 2000
Completion
Jan 31, 2000

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92658-

Find similar trials in Newport Beach, CA

By research site
Hoag Memorial Hospital Presbyterian· Newport Beach, CA

Related Studies